RNAZ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RNAZ is not a good buy right now. There are no Intellectia buy signals, the near-term pattern-based forecast skews bearish (higher odds of declines over the next day/week), and price is sitting below the key pivot (10.393), making the risk/reward unattractive for an impatient buyer looking for immediate upside.
Trend/price context: RNAZ is trading at 9.6 in a down market (S&P 500 -0.71%). Key levels show the stock is below the pivot at 10.393, which is a bearish/defensive posture unless it reclaims that level. Support sits at S1 8.77 (then S2 7.767); resistance is R1 12.017 (then R2 13.02). Momentum: MACD histogram is positive (0.246) but positively contracting, implying upside momentum is fading rather than strengthening. RSI(6) at 55.84 is neutral—no oversold bounce signal. Moving averages: Converging MAs suggest consolidation rather than a clean uptrend. Quant/pattern outlook: Similar candlestick-pattern analysis implies an 80% chance of -3.3% next day, -5.14% next week, and -1.88% next month—skewing odds to further weakness rather than an immediate breakout.
Intellectia Proprietary Trading Signals
Upcoming earnings (2026-02-12 after hours) could act as a volatility catalyst if results or pipeline updates surprise to the upside.
can pressure micro-cap biotech names if updates disappoint.
Latest reported quarter: 2025/Q3. Revenue was 0 (no YoY growth). Net income was -4,856,051 (reported as improved YoY), but EPS dropped to -5.82 (down -96.02% YoY). Overall: still pre-revenue with ongoing losses and weakening per-share earnings trend, which is not supportive for a near-term buy setup.
No analyst rating or price target change data was provided, so there is no visible recent Wall Street upgrade/downgrade trend to support a buy thesis. Wall Street pros/cons view based on available info: Pros—earnings date can provide a catalyst; Cons—pre-revenue, losses, deteriorating EPS, and no confirming technical/signal-based buy setup. Politicians/influential trading: No recent congress trading data available. Hedge funds/insiders: Neutral with no significant recent trends.
